You are here:  Home » Research » Parkinson's Disease Research Web » Udall Centers » Annual Meetings » 13th Annual Udall Center Directors' Meeting » 

Skip secondary menu

13th Annual Udall Center Directors' Meeting Agenda


Translating Research to Treatment for Parkinson’s Disease and Related Disorders

September 13-14, 2011
Grand Hyatt
Washington, D.C.
Workshop   Participant List   Executive Summary


Tuesday, September 13, 2011

UC3 Members and Center Administrators Meetings

8:00 am
Session 1:  Udall Center Coordinating Committee (UC3) Meeting
John Q.Trojanowski, MD, PhD, UC3 Chair
Director, University of Pennsylvania Udall Center
Session 2:  Udall Center Administrators Meeting
M. Kathryn Jedrziewski, PhD, Chair
Center Administrator, University of Pennsylvania Udall Center
General Session:  All Participants (Independence Ballroom F-H)
9:30 a.m.
Registration and Continental Breakfast for general participants
10:00 a.m.
Opening Remarks/NINDS Update
Story C. Landis, PhD
Director, NINDS
10:45 a.m.
Break

Poster Presentation:
National Brain and Tissue Resource for PD and Related Disorders
Thomas G. Beach, MD, PhD Banner Sun Health Research Institute
Charles H. Adler, MD, PhD, Mayo Clinic Scottsdale
11:00 a.m.
Introductory Udall Center Presentation: Functional Brain Networks: A Novel Approach to Address Clinical Challenges in PD
David Eidelberg, MD
Director, Center for Neurosciences and Udall Center
The Feinstein Institute for Medical Research
11:45 a.m.
Lunch Presentation

Biomedical Research:  A Congressional Update
Guest Speaker: Amy Comstock Rick, Esq.
Chief Executive Officer, Parkinson’s Action Network
Translating PD Research to Treatment: Industry Perspective

             
Moderator: John Q. Trojanowski, MD, PhD,
Chair, UC3 and Director, University of Pennsylvania Udall Center
1:00 p.m.
Passive Immunization Targeting α-Synuclein for Parkinson's Disease Therapy
Dora Games, PhD
Vice President of Pharmacology
Neotope Biosciences, Elan Pharmaceuticals
1:40 p.m.
Improving Proteostasis to Ameliorate Lewy Body Formation In Parkinson's Disease
Peter H. Reinhart, PhD
President and Chief Scientific Officer
Proteostasis Therapeutics
2:20 p.m.
Drug Development for Parkinson's Disease: a Merck Perspective
Ian Reynolds, PhD
Director, Merck Research Laboratories
3:00 p.m.
BREAK
Brainstorming Session:  A Role for Udall Centers in Therapeutic Development

             
Moderator: Walter J. Koroshetz, MD, Deputy Director, NINDS

Selected ideas will be highlighted in a 15-minute presentation by the Center Director or designated Center investigator, followed by discussion of needs and roadblocks to the translation of research into PD treatments at Udall Centers.
3:30 p.m.
Targeting Cell-To-Cell Transmission of Pathological Alpha-Synuclein for the Treatment of Parkinson’s Disease (PD) and PD Dementia (PDD)
Virginia M-Y Lee, PhD, University of Pennsylvania Udall Center
3:45 p.m.
Target Identification and Validation for Parkinson’s Disease Drug Development
Ted M. Dawson, MD, PhD, Director, Johns Hopkins Udall Center
4:00 p.m.
L-Type Calcium Channels in Parkinson’s Disease Pathogenesis
D. James Surmeier, PhD, Director, Northwestern University Udall Center
4:15 p.m.
Discussion: Opportunities for Therapeutic Development at Udall Centers
Udall Center Directors and meeting participants
5:00 p.m.
Strategies for Advancing Parkinson's Disease Research
Todd Sherer, PhD
Chief Executive Officer
Michael J. Fox Foundation for Parkinson’s Disease Research
5:30 p.m.
Informal Discussion/Mixer (Cash bar at The Grand Café Gazebo, Lagoon Level)
6:30 p.m.
Dinner (The Grand Café; registration required)
Wednesday, September 14, 2011

7:30 a.m.
Continental Breakfast

Udall Center Collaborative Supplements: Updates, Future Directions
Moderator: Beth-Anne Sieber, PhD, NINDS Udall Centers Program Director
8:30 a.m.
Mitochondrial dysfunction in substantia nigra dopamine neurons
D. James Surmeier, PhD, Director, Northwestern Udall Center
David Sulzer, PhD, Columbia University Udall Center
9:00 a.m.
Genetic modifiers of cognitive function in Parkinson’s disease
Presenter: Cyrus P. Zabetian, MD, PANUC- University of Washington
Collaborator: Beate Ritz, MD, PhD, UCLA Udall Center
9:30 a.m.
Break
10:00 a.m.
Validation of MRI for staging clinical severity of Lewy Body spectrum disorders
Collaborator: David Eidelberg, MD, Director, Feinstein Institute for Medical Research Udall Center
Presenter: Rachel Gross, MD, University of Pennsylvania
10:30 a.m.
Harmonization of cognitive testing in Parkinson’s disease
Presenter: James Leverenz, MD, PANUC- University of Washington
Collaborator: Andrew D. Siderowf, MD, University of Pennsylvania
11:30 a.m.
Lunch and informal discussion
11:30 a.m.
NINDS - NGOs Meeting (Independence Ballroom I)
Discussion topics: PD project updates and next steps
             
Moderator: Margaret L. Sutherland, PhD, NINDS Program Director
1:00 p.m.
NINDS Contract for neurotherapeutics testing in standardized animal models
Discussant: D. James Surmeier, PhD
Director, Northwestern University Udall Center
1:45 p.m.
Parkinson's Disease Induced Pluripotent Stem Cell (iPSC) Consortium
Discussant: Ted M. Dawson, MD, PhD
Director, Johns Hopkins University School of Medicine Udall Center
2:30 p.m.
Autopsy-verified PD Genome-Wide Analysis Studies (GWAS)
Discussant: Jeffery M. Vance, MD, PhD
Director, University of Miami Udall Center
3:15 p.m.
Next Steps: Looking Forward to 2012
Robert E. Burke, MD, Columbia University, UC3 Chair 2012
Beth-Anne Sieber, PhD, NINDS
3:30 p.m.
Adjournment

Last updated May 9, 2013